These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25885326

  • 41. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ, GARDEL Study Group.
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [Abstract] [Full Text] [Related]

  • 42. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    Ruane PJ, Brinson C, Ramgopal M, Ryan R, Coate B, Cho M, Kakuda TN, Anderson D, INROADS study investigators.
    HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
    [Abstract] [Full Text] [Related]

  • 43. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
    Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS.
    PLoS One; 2014 May; 9(5):e96187. PubMed ID: 24825167
    [Abstract] [Full Text] [Related]

  • 44. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A, Galli L, Bigoloni A, Bossolasco S, Guffanti M, Maillard M, Carini E, Salpietro S, Spagnuolo V, Gianotti N, Lazzarin A, Castagna A.
    J Int AIDS Soc; 2014 May; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [Abstract] [Full Text] [Related]

  • 45. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
    Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, Sension M, Protocol AI424-009 Study Group.
    AIDS; 2003 Jun 13; 17(9):1339-49. PubMed ID: 12799555
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
    Arrizabalaga J, Arazo P, Aguirrebengoa K, García-Palomo D, Chocarro A, Labarga P, Muñoz-Sánchez MJ, Echevarría S, Oteo JA, Uriz J, Letona S, Fariñas MC, Peralta G, Pinilla J, Ferrer P, Alvarez ML, Iribarren JA.
    HIV Clin Trials; 2007 Jun 13; 8(5):328-36. PubMed ID: 17956834
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
    Gantner P, Bani-Sadr F, Garraffo R, Roger PM, Treger M, Jovelin T, Pugliese P, Rey D, Dat’AIDS cohort.
    PLoS One; 2016 Jun 13; 11(10):e0164240. PubMed ID: 27798641
    [Abstract] [Full Text] [Related]

  • 50. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
    Negredo E, Estrada V, Domingo P, Gutiérrez MD, Mateo GM, Puig J, Bonjoch A, Ornelas A, Echeverría P, Estany C, Toro J, Clotet B.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):844-849. PubMed ID: 27999056
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group.
    Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
    Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, Giordano M.
    J Acquir Immune Defic Syndr; 2004 Jun 01; 36(2):684-92. PubMed ID: 15167287
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.
    Echeverría P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E.
    HIV Med; 2017 Nov 01; 18(10):782-786. PubMed ID: 28671337
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.